Model-based dietary optimization for late-stage, levodopa-treated, Parkinson’s disease patients

npj Systems Biology and Applications

Volumn 2, Issue , 2016, Pages

  Guebila, Marouen Ben ^a   Thiele, Ines ^a  

^a UNIVERSITY OF LUXEMBOURG   (Luxembourg)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85052707536     PISSN: None     EISSN: 20567189     Source Type: Journal    
DOI: 10.1038/npjsba.2016.13     Document Type: Article

References (49)

1. Lennernas, H. Human intestinal permeability. J. Pharm. Sci. 87, 403–410 (1998).
2. Brooks, D. J. Optimizing levodopa therapy for Parkinson's disease with levodopa/ carbidopa/entacapone: implications from a clinical and patient perspective. Neuropsychiatr. Dis. Treat. 4, 39–47 (2008).
3. Eisenhofer, G. et al. Substantial production of dopamine in the human gastrointestinal tract. J. Clin. Endocrinol. Metab. 82, 3864–3871 (1997).
4. Fahn, S. & Poewe, W. Levodopa: 50 years of a revolutionary drug for Parkinson disease. Mov. Disord. 30, 1–3 (2015).
5. Nutt, J. G., Woodward, W. R., Hammerstad, J. P., Carter, J. H. & Anderson, J. L. The ‘on-off’ phenomenon in Parkinson’s disease. Relation to levodopa absorption and transport. N. Engl. J. Med. 310, 483–488 (1984).
6. Ishihara, L. & Brayne, C. A systematic review of nutritional risk factors of Parkinson’s disease. Nutr. Res. Rev. 18, 259–282 (2005).
7. Contin, M. & Martinelli, P. Pharmacokinetics of levodopa. J. Neurol. 257, S253–S261 (2010).
8. Cereda, E., Barichella, M., Pedrolli, C. & Pezzoli, G. Low-protein and proteinredistribution diets for Parkinson's disease patients with motor fluctuations: a systematic review. Mov. Disord. 25, 2021–2034 (2010).
9. Camargo, S. M. et al. The molecular mechanism of intestinal levodopa absorption and its possible implications for the treatment of Parkinson's disease. J. Pharmacol. Exp. Ther. 351, 114–123 (2014).
10. Jones, H. & Rowland-Yeo, K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst. Pharmacol. 2, e63 (2013).
11. Agoram, B., Woltosz, W. S. & Bolger, M. B. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv. Drug Deliv. Rev. 50 Suppl 1, S41–S67 (2001).
12. O'Brien, E. J., Monk, J. M. & Palsson, B. O. Using genome-scale models to predict biological capabilities. Cell 161, 971–987 (2015).
13. Schellenberger, J. et al. Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0. Nat. Protoc. 6, 1290–1307 (2011).
14. Thiele, I. & Palsson, B. O. A protocol for generating a high-quality genome-scale metabolic reconstruction. Nat. Protoc. 5, 93–121 (2010).
15. Beard, D. A., Liang, S. D. & Qian, H. Energy balance for analysis of complex metabolic networks. Biophys. J. 83, 79–86 (2002).
16. Sahoo, S. & Thiele, I. Predicting the impact of diet and enzymopathies on human small intestinal epithelial cells. Hum. Mol. Genet. 22, 2705–2722 (2013).
17. Duarte, N. C. et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc. Natl Acad. Sci. USA 104, 1777–1782 (2007).
18. Thiele, I. et al. A community-driven global reconstruction of human metabolism. Nat. Biotechnol. 31, 419–425 (2013).
19. Sahoo, S., Aurich, M. K., Jonsson, J. J. & Thiele, I. Membrane transporters in a human genome-scale metabolic knowledgebase and their implications for disease. Front. Physiol. 5, 91 (2014).
20. Sahoo, S., Haraldsdottir, H. S., Fleming, R. M. & Thiele, I. Modeling the effects of commonly used drugs on human metabolism. FEBS J. 282, 297–317 (2015).
21. Lennernas, H. et al. The effect of L-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man. Br. J. Clin. Pharmacol. 35, 243–250 (1993).
22. Hardoff, R. et al. Gastric emptying time and gastric motility in patients with Parkinson's disease. Mov. Disord. 16, 1041–1047 (2001).
23. Bos, C. et al. Postprandial kinetics of dietary amino acids are the main determinant of their metabolism after soy or milk protein ingestion in humans. J. Nutr. 133, 1308–1315 (2003).
24. Verrey, F., Meier, C., Rossier, G. & Kuhn, L. C. Glycoprotein-associated amino acid exchangers: broadening the range of transport specificity. Pflugers Arch. 440, 503–512 (2000).
25. Gelfin, E. et al. D-serine adjuvant treatment alleviates behavioural and motor symptoms in Parkinson's disease. Int. J. Neuropsychopharmacol. 15, 543–549 (2012).
26. Krauss, M. et al. Integrating cellular metabolism into a multiscale whole-body model. PLoS Comput. Biol. 8, e1002750 (2012).
27. Adibi, S. A., Gray, S. J. & Menden, E. The kinetics of amino acid absorption and alteration of plasma composition of free amino acids after intestinal perfusion of amino acid mixtures. Am. J. Clin. Nutr. 20, 24–33 (1967).
28. Nagayama, H. et al. Pharmacokinetics of levodopa before and after gastrointestinal resection in parkinson's disease. Case Rep. Neurol. 7, 181–185 (2015).
29. van der Graaf, P. H. & Benson, N. Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharm. Res. 28, 1460–1464 (2011).
30. Contin, M. et al. Levodopa therapy monitoring in patients with Parkinson disease: a kinetic-dynamic approach. Ther. Drug Monit. 23, 621–629 (2001).
31. Fasano, A., Visanji, N. P., Liu, L. W., Lang, A. E. & Pfeiffer, R. F. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol. 14, 625–639 (2015).
32. Doi, H. et al. Plasma levodopa peak delay and impaired gastric emptying in Parkinson’s disease. J. Neurol. Sci. 319, 86–88 (2012).
33. Sousa, T. et al. The gastrointestinal microbiota as a site for the biotransformation of drugs. Int. J. Pharm. 363, 1–25 (2008).
34. Rivera-Calimlim, L., Dujovne, C. A., Morgan, J. P., Lasagna, L. & Bianchine, J. R. L-dopa treatment failure: explanation and correction. Br. Med. J. 4, 93–94 (1970).
35. Hashim, H. et al. Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson's disease. PLoS ONE 9, e112330 (2014).
36. Pierantozzi, M. et al. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology 66, 1824–1829 (2006).
37. Foltynie, T. et al. Impact of Duodopa on quality of life in advanced Parkinson's disease: a UK case series. Parkinsons Dis. 2013, 362908 (2013).
38. Sanger, G. J. et al. GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility. Neurogastroenterol. Motil. 21, 657–664, e30-1 (2009).
39. Waller, D. G., Usman, F., Renwick, A. G., Macklin, B. & George, C. F. Oral amino acids and gastric emptying: an investigation of the mechanism of levodopa-induced gastric stasis. Br. J. Clin. Pharmacol. 32, 771–773 (1991).
40. Adibi, S. A. & Mercer, D. W. Protein digestion in human intestine as reflected in luminal, mucosal, and plasma amino acid concentrations after meals. J. Clin. Invest. 52, 1586–1594 (1973).
41. Robertson, D. R. et al. The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers. Br. J. Clin. Pharmacol. 31, 413–417 (1991).
42. Growdon, J. H., Melamed, E., Logue, M., Hefti, F. & Wurtman, R. J. Effects of oral L-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson’s disease. Life Sci. 30, 827–832 (1982).
43. Nagashima, Y., Kondo, T., Sakata, M., Koh, J. & Ito, H. Effects of soybean ingestion on pharmacokinetics of levodopa and motor symptoms of Parkinson's disease— In relation to the effects of Mucuna pruriens. J. Neurol. Sci. 361, 229–234 (2016).
44. Peters, S. A. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis. Clin. Pharmacokinet. 47, 261–275 (2008).
45. Keller, G. A. et al. Comparative bioavailability of 2 tablet formulations of levodopa/benserazide in healthy, fasting volunteers: a single-dose, randomizedsequence, open-label crossover study. Clin. Ther. 33, 500–510 (2011).
46. Massey, F. J. The Kolmogorov-Smirnov test for goodness of fit. J. Am. Stat. Assoc. 46, 68–78 (1951).
47. Varma, A. & Palsson, B. O. Stoichiometric flux balance models quantitatively predict growth and metabolic by-product secretion in wild-type Escherichia coli W3110. Appl. Environ. Microbiol. 60, 3724–3731 (1994).
48. Mahadevan, R., Edwards, J. S. & Doyle, F. J. 3rd Dynamic flux balance analysis of diauxic growth in Escherichia coli. Biophys. J. 83, 1331–1340 (2002).
49. Covert, M. W., Xiao, N., Chen, T. J. & Karr, J. R. Integrating metabolic, transcriptional regulatory and signal transduction models in Escherichia coli. Bioinformatics 24, 2044–2050 (2008).